Buclizine

DB00354

small molecule approved

Deskripsi

Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects L6220, belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957.L6217 Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.A178102 In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy. A178105, A178108

Struktur Molekul 2D

Berat 433.028
Wujud liquid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly absorbed following oral administration.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

809 Data
Aclidinium The risk or severity of adverse effects can be increased when Buclizine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Buclizine.
Mirabegron The risk or severity of urinary retention can be increased when Buclizine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Buclizine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Buclizine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Buclizine.
Tiotropium The risk or severity of adverse effects can be increased when Buclizine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Buclizine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Buclizine is combined with Umeclidinium.
Benzylpenicilloyl polylysine Buclizine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Buclizine.
Glycopyrronium The risk or severity of adverse effects can be increased when Buclizine is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum toxin type A.
Glucagon Buclizine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Buclizine may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Buclizine is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Buclizine is combined with Ramosetron.
Amphetamine Amphetamine may decrease the sedative activities of Buclizine.
Phentermine Phentermine may decrease the sedative activities of Buclizine.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Buclizine.
Benzphetamine Benzphetamine may decrease the sedative activities of Buclizine.
Diethylpropion Diethylpropion may decrease the sedative activities of Buclizine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Buclizine.
Mephentermine Mephentermine may decrease the sedative activities of Buclizine.
MMDA MMDA may decrease the sedative activities of Buclizine.
Midomafetamine Midomafetamine may decrease the sedative activities of Buclizine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Buclizine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Buclizine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Buclizine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Buclizine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Buclizine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Buclizine.
Metamfetamine Metamfetamine may decrease the sedative activities of Buclizine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Buclizine.
Ritobegron Ritobegron may decrease the sedative activities of Buclizine.
Mephedrone Mephedrone may decrease the sedative activities of Buclizine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Buclizine.
Gepefrine Gepefrine may decrease the sedative activities of Buclizine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Buclizine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Buclizine.
Naltrexone The risk or severity of adverse effects can be increased when Buclizine is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Buclizine is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Buclizine is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Buclizine is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Buclizine is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Buclizine is combined with Hydromorphone.
Meperidine The risk or severity of adverse effects can be increased when Buclizine is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Buclizine is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Buclizine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Buclizine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Buclizine is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Buclizine is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Buclizine is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Buclizine is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Buclizine is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Buclizine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Buclizine is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Buclizine is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Buclizine is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Buclizine is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Buclizine is combined with Dezocine.
Methadyl acetate The risk or severity of adverse effects can be increased when Buclizine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Buclizine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Buclizine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Buclizine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Buclizine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Buclizine is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Buclizine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Buclizine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Buclizine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Buclizine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Buclizine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Buclizine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Buclizine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Buclizine is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Buclizine is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Buclizine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Buclizine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Buclizine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Buclizine is combined with Carfentanil, C-11.
Methadone The risk or severity of adverse effects can be increased when Buclizine is combined with Methadone.
Levacetylmethadol The risk or severity of adverse effects can be increased when Buclizine is combined with Levacetylmethadol.
Benzhydrocodone The risk or severity of adverse effects can be increased when Buclizine is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Buclizine is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Buclizine.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Buclizine.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Buclizine.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Buclizine is combined with Trihexyphenidyl.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Buclizine is combined with Oxyphencyclimine.
Procyclidine The risk or severity of adverse effects can be increased when Buclizine is combined with Procyclidine.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Buclizine is combined with Methscopolamine bromide.
Darifenacin The risk or severity of adverse effects can be increased when Buclizine is combined with Darifenacin.

Target Protein

Histamine H1 receptor HRH1
Muscarinic acetylcholine receptor M1 CHRM1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 21572667
    Babu TA: Buclizine is back again! This time as a pediatric appetite stimulant. Indian J Pharmacol. 2011 Apr;43(2):219. doi: 10.4103/0253-7613.77383.
  • PMID: 3556262
    Adam EI: A treatment for the acute migraine attack. J Int Med Res. 1987 Mar-Apr;15(2):71-5. doi: 10.1177/030006058701500202.
  • PMID: 13374321
    DURHAM MP: Clinical trial of buclizine hydrochloride for vomiting of pregnancy. Br Med J. 1956 Dec 1;2(5004):1276-7. doi: 10.1136/bmj.2.5004.1276.

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Bucladin
  • Bucladin-S
  • Longifene Syrup — Novartis India

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul